45 completed, 11 recruiting, 5 terminated, 3 unknown. 26 Phase 4, 21 Phase 2, 10 Phase 1, 7 Phase 3, 5 Early Phase 1.
Follow suvorexant: new trials by email Literature Review of suvorexant trials Research Report on suvorexant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Suvorexant 3 - PE-PC Suvorexant, Placebo, Prolonged Exposure Therapy for Primary Care (PE-PC) - PTSD - Post Traumatic Stress Disorder, Insomnia | Phase 4 | Not yet recruiting | Northern California Institute of Research and Education | 142 | 2026-09-01 | 2026-07-07 |
| The Effects of Orexin Antagonism on Fear Extinction in PTSD Suvorexant, Placebo - Insomnia, PTSD | Phase 4 | Not yet recruiting | VA Office of Research and Development | 40120 | 2026-06-01 | 2026-06-02 |
| Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking Suvorexant 10 mg, Placebo - Alcohol Use Disorder | Phase 2 | Recruiting | Ohio State University | 250 | 2025-12-04 | 2026-09-21 |
| A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) Suvorexant, Placebo - Insomnia | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 300 | 2025-10-09 | 2026-09-21 |
| Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial Suvorexant (dual orexin receptor antagonist) - Suicide Risk, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Marianne Goodman | 30 | 2025-09-01 | 2025-09-25 |
| Suvorexant for Treatment of AUD and PTSD Suvorexant, Placebo - Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD) | Phase 2 | Recruiting | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 76 | 2025-07-16 | 2026-10-14 |
| Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study) Suvorexant - Cue-reactivity, Cannabis Use Disorder | Phase 4 | Completed | Massachusetts General Hospital | 20 | 2025-03-10 | 2026-07-01 |
| Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients Best Practice, Electronic Health Record Review, Interview - Advanced Malignant Solid Neoplasm, Delirium | Phase 4 | Withdrawn | Mayo Clinic | 2025-02-26 | 2025-05-01 | |
| Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms Siemens 3T PRISMA MR Scanner, PET/CT Scanner, Suvorexant - Healthy Volunteers, Alcohol Use Disorder (AUD) | Phase 1 / Phase 2 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 180 | 2024-11-21 | 2026-10-19 |
| Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors Suvorexant Tablets, Placebo Control - Breast Cancer, Insomnia | Phase 4 | Terminated | Medical University of South Carolina | 6 | 2024-09-20 | 2026-08-12 |
| Suvorexant and Alcohol Alcohol, Placebo, Suvorexant - Alcohol Use Disorder | Early Phase 1 | Recruiting | William Stoops | 30 | 2024-06-07 | 2026-06-08 |
| Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo) - Insomnia | Phase 2 | Completed | University of Maryland, Baltimore | 40 | 2023-10-09 | 2025-10-30 |
| Trial of Suvorexant for Sleep in Children With Autism Suvorexant, Placebo - Autism, Autism Spectrum Disorder | Phase 2 | Recruiting | Stanford University | 26 | 2023-08-09 | 2026-03-27 |
| Measuring Acute Drug Demand in Humans Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug) - Opioid Use Disorder, Opioid Dependence | Early Phase 1 | Recruiting | University of Maryland, Baltimore | 75 | 2023-08-08 | 2026-06-23 |
| REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant Suvorexant 20 mg, Placebo - Delirium in Old Age | Phase 2 | Completed | Duke University | 142 | 2023-06-28 | 2026-01-15 |
| Efficacy of Suvorexant on Post-operative Sleep Disturbance Suvorexant, Placebo - Postoperative Insomnia, Postoperative Delirium | Phase 4 | Completed | Columbia University | 100 | 2023-05-01 | 2026-07-23 |
| The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder suvorexant (SUVO), Placebo - Methamphetamine Use Disorder | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 7 | 2023-03-09 | 2025-04-29 |
| Orexin s Role in the Neurobiology of Substance Use Disorder Belsomra, Placebo, Methylphenidate - Nicotine Dependence | Not applicable | Recruiting | National Institute on Drug Abuse (NIDA) | 140 | 2023-02-15 | 2026-09-11 |
| Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia Suvorexant, Placebo - Insomnia, Metabolic Health | Phase 4 | Completed | Brigham and Women's Hospital | 31 | 2023-01-06 | 2026-04-16 |
| Suvorexant for Opioid/Stimulant Co-use Suvorexant (dual orexin receptor antagonist), Placebo - Opioid Use Disorder, Stimulant Use Disorder | Phase 2 | Completed | Johns Hopkins University | 20 | 2022-12-01 | 2025-12-23 |
Showing 20 of 69. Sign in to see all of them.
Sleep Initiation and Maintenance Disorders (40) · Alcoholism (7) · Opioid-Related Disorders (6) · Stress Disorders, Post-Traumatic (6) · Parasomnias (4) · Delirium (3) · Sleep Wake Disorders (3) · Alzheimer Disease (2) · Bipolar Disorder (2) · Depressive Disorder, Major (2) · Emergence Delirium (2) · Plaque, Amyloid (2) · Restless Legs Syndrome (2) · Substance-Related Disorders (2) · Tobacco Use Disorder (2)
Merck Sharp & Dohme LLC (12) · Johns Hopkins University (4) · Massachusetts General Hospital (4) · The University of Texas Health Science Center, Houston (3) · Brigham and Women's Hospital (2) · Henry Ford Health System (2) · Howard University (2) · Ohio State University (2) · Stanford University (2) · University of California, San Francisco (2) · University of Maryland, Baltimore (2) · VA Office of Research and Development (2) · William Stoops (2) · Beth Israel Deaconess Medical Center (1) · Burdick, Daniel, M.D. (1)
United States (53) · Canada (2) · Japan (2) · Australia (1) · Netherlands (1) · Spain (1)
Andrew S Huhn, PhD (2) · Brendan Lucey, MD (2) · Sabra S Inslicht, PhD (2) · William W Stoops, PhD (2) · Amy C Janes, Ph.D. (1) · Amy Janes, PhD (1) · Andrew Goddard, MD (1) · Andrew Lawrence (1) · Andrew S Huhn, Ph.D. (1) · Angelo Sambunaris, MD (1) · Antonio Y. Hardan, MD (1) · Balachundhar Subramaniam (1) · Barbara J. Mason, Ph.D. (1)
PMID 28265715, PMID 28427826, PMID 36529106, PMID 25526970, PMID 27198953, PMID 27397664, PMID 29112763, PMID 30522875, PMID 31926466, PMID 33210445, PMID 23197752, PMID 24680372, PMID 25661282, PMID 26194728, PMID 31538599, PMID 31944580, PMID 31992394, PMID 32484552, PMID 32690536, PMID 33189083, PMID 34480579, PMID 35022783, PMID 35748777, PMID 39150711, PMID 39260076, PMID 39731508, PMID 40081971, PMID 40640892, PMID 41490112, PMID 41630040, PMID 42337809
2015 (1), I01CX001814 (1), K01MH110647 (1), P50HD109861 (1), P60AA006420 (1), R01AA030775 (1), R01AA032711 (1), R01DA048617 (1), R01DA055634 (1), R21AA030097 (1), U01HL150835 (1), UG3DA048734 (1), UH3DA048734 (1)